TAKARA BIO INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,015 JPY | +0.10% |
|
+6.17% | -18.93% |
| Mar. 18 | Takara Bio Inc.(TSE:4974) dropped from FTSE All-World Index | CI |
| Feb. 15 | Takara Bio's Attributable Income Falls 98.9% in Fiscal Nine Months | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
TAKARA BIO INC. is a Japan-based company principally engaged in bio-industry support business and gene medicine business. The Company operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.
Calendar
2024-05-09
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1,015
JPY
Average target price
1,600
JPY
Spread / Average Target
+57.64%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.93% | 776M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- 4974 Stock
- News Takara Bio Inc.
- Takara Bio's Attributable Income Falls 98.9% in Fiscal Nine Months
